Riyad Capital

Riyad Capital is the investment arm of Riyad Bank, one of Saudi Arabia’s largest commercial banks, operating private equity, asset management, and public market funds with significant deployment into Saudi healthcare and regional tech. Stage focus is Series A through growth, with check sizes that scale into institutional PE territory but also include venture-stage commitments. AI is a stated interest, particularly in the context of Saudi Arabia’s broader Vision 2030 digital transformation agenda. Healthcare exposure spans digital health, healthcare software, tech-enabled care delivery, and growth-stage clinical platforms. The right founder for Riyad Capital is a healthcare or healthtech operator with real revenue, a clear path to scale inside Saudi Arabia, and the governance maturity to absorb institutional capital, ideally with the optionality of either Tadawul listing or strategic acquisition by a Saudi or regional payer or provider group. The wrong founder is a pre-revenue seed-stage company, since Riyad Capital does not lead small rounds, or a US-pedigreed team without a Saudi-market thesis. Intro paths run through Riyadh’s institutional capital community: investment bankers active in the Kingdom, the PIF and Sanabil ecosystems, regional placement agents, and law firms such as Al Tamimi or Khoshaim. Co-investing funds including STV, Impact46, Wa’ed Ventures, and Jadwa Investment are also natural connectors. Direct outreach to Riyad Capital partners through LinkedIn is acknowledged but conversion is materially better through institutional referral. In the pitch, lead with audited financials or a credible path to audit-ready reporting, the use of proceeds tied explicitly to Saudi market expansion or new product lines, and a clear-eyed view of Saudi healthcare regulatory dynamics including SFDA, MOH, NPHIES, and the mandatory health insurance regime. Show that you understand Vision 2030 health-sector privatization and the Health Sector Transformation Program, and how those tailwinds map to your business. Be explicit about Sharia compliance posture and Saudization implications for your hiring plan. Caveats include the longer diligence cycles typical of bank-affiliated institutional investors, the structural preference for revenue businesses over pure technology bets, and the reality that Riyad Capital’s deal cadence varies materially by fund vintage and bank-strategic priority. For mature healthcare businesses, this is a credible Saudi institutional partner; for venture-stage companies, the door is narrower than the firm’s broad mandate suggests.